Publications

Featured Publications

INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:

COVID-19

Title Disease Target Product
Immunogenicity of a DNA vaccine candidate for COVID-19
Nature Communications — May 2020
COVID-19 INO-4800
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
Open Forum Infectious Diseases — December 2021
COVID-19 INO-4800
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial
The Journal of Infectious Diseases — January 2022
COVID-19 INO-4800
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants
npj Vaccines — October 2021
COVID-19 INO-4800